Danielle Gubbay
Danielle is a Senior Investment Manager from Foresight Group and recently joined Inoviv as an Investor Observer. She is an experienced entrepreneur (ex-CEO) and has invested in multiple early-stage businesses across industries. Danielle holds a BEc from the University of Sydney and a Juris Doctorate from the University of Technology, Sydney.
Vanela Bushi
Vanela holds the position of Investor Advisor at Inoviv. She has more than 15+ years of experience advising and operating across biotechnology and health technology. Vanela holds an MSc in Bioengineering & Medical Physics from Imperial College London and BSc in Physics, Immunology & Microbiology from McGill University.
Rob Kniaz
Rob is a partner at Hoxton Ventures, one of the earliest backers of unicorn startups including Deliveroo, Babylon Health and DarkTrace, and joins Inoviv as an investor director. A dual US/UK national, he holds a BS in Computer Science from the University of Maryland and a Masters certificate in Management Science & Engineering from Stanford […]
Gustavo Salem
Gustavo is a seasoned board member with nearly 30 years of executive experience in life science and clinical diagnostics. He excels in P&L management, product development, manufacturing operations, and sales/marketing. Known for his strategic vision, Gustavo is adept at bringing new technologies to market and fostering motivated teams poised for success.
Ernestas Sirka
Ernestas Sirka is a seasoned biochemistry expert with extensive experience in clinical test development, distinguished by roles at Pfizer and UCL. Notably, he has pioneered the development of four clinical tests that continue to underpin modern clinical practice, cementing his reputation as a trailblazer in medical diagnostics. Ernestas’ pursuit of utilizing novel scientific applications to […]
Michael Dove
Michael is a dynamic leader with a strong track record of success in the pharmaceutical and biotechnology industries. As Inoviv’s CEO, Michael drives the company’s strategic vision and growth. Prior to this, Michael played instrumental roles in securing multi-million dollar deals within the pharmaceutical sector. He has project-managed over $10 million worth of technology projects […]
